Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H17N3O2S.ClH |
| Molecular Weight | 339.84 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.O=C(N[C@H]1CN2CCC1CC2)C3=CNC4=C(SC=C4)C3=O
InChI
InChIKey=XGVADZZDFADEOO-YDALLXLXSA-N
InChI=1S/C15H17N3O2S.ClH/c19-13-10(7-16-11-3-6-21-14(11)13)15(20)17-12-8-18-4-1-9(12)2-5-18;/h3,6-7,9,12H,1-2,4-5,8H2,(H,16,19)(H,17,20);1H/t12-;/m0./s1
| Molecular Formula | C15H17N3O2S |
| Molecular Weight | 303.379 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pumosetrag is a novel, orally active and selective 5-HT 3 agonist. It is a partial agonist in rats and guinea-pig and a full agonist in the mouse, suggesting important species differences in 5-HT3 receptor structure. Pumosetrag had been in phase II clinical trials for the treatment of gastroesophageal reflux disease and irritable bowel syndrome. No serious adverse events were reported. Diarrhea was not more common on the drug and only one subject experienced pruritus. All researches on this drug candidate are discontinued.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1899 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14616171 |
0.8 nM [Ki] | ||
Target ID: 483776.0 Gene Symbol: CHRM1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14616171 |
7.7 µM [Ki] | ||
Target ID: 403858.0 Gene Symbol: CHRM2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14616171 |
3.3 µM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| inconclusive [IC50 >10 uM] | ||||
| inconclusive [IC50 >10 uM] | ||||
| inconclusive [IC50 >10 uM] | ||||
| inconclusive [IC50 >10 uM] | ||||
| inconclusive [IC50 >10 uM] | ||||
| yes [IC50 9.3 uM] |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study. | 2014-01 |
|
| Inotropic effects of prokinetic agents with 5-HT(4) receptor agonist actions on human isolated myocardial trabeculae. | 2012-04-09 |
|
| Effects of the novel 5-HT3 agonist MKC-733 on the rat, mouse and guinea pig digestive tract. | 2008 |
|
| Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. | 2007-05 |
|
| Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. | 2005-12 |
|
| Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. | 2003-11-15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24001105
0.2, 0.5, or 0.8 mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17952012
In the presence of methysergide (1 mol/l) and GR125487 (0.1 mol/l), MKC-733 appeared to have little to no contractile effect in the jejunum (E max = 11.85 %), ileum (E max = 9.65 %) and distal colon of the rat (E max = 14.30 %).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:27:50 GMT 2025
by
admin
on
Mon Mar 31 21:27:50 GMT 2025
|
| Record UNII |
UVW44TKU66
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
194093-42-0
Created by
admin on Mon Mar 31 21:27:50 GMT 2025 , Edited by admin on Mon Mar 31 21:27:50 GMT 2025
|
PRIMARY | |||
|
UVW44TKU66
Created by
admin on Mon Mar 31 21:27:50 GMT 2025 , Edited by admin on Mon Mar 31 21:27:50 GMT 2025
|
PRIMARY | |||
|
DTXSID00173026
Created by
admin on Mon Mar 31 21:27:50 GMT 2025 , Edited by admin on Mon Mar 31 21:27:50 GMT 2025
|
PRIMARY | |||
|
DBSALT002188
Created by
admin on Mon Mar 31 21:27:50 GMT 2025 , Edited by admin on Mon Mar 31 21:27:50 GMT 2025
|
PRIMARY | |||
|
154103
Created by
admin on Mon Mar 31 21:27:50 GMT 2025 , Edited by admin on Mon Mar 31 21:27:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |